Maurice Zauderer, Ph. D. – President and CEO

Dr. Zauderer co-founded Vaccinex and has served as President, Chief Executive Officer and a director of Vaccinex since its inception. He is the inventor of core technologies for construction of representative cDNA libraries in vaccinia virus and discovery of fully human monoclonal antibodies. Prior to founding Vaccinex, Dr. Zauderer was a Professor at the University of Rochester and has also held faculty appointments at Columbia University. During his academic career, Dr. Zauderer held the position of visiting scientist at the Laboratory of Cell Biology (Rome, Italy), the Ontario Cancer Institute (Toronto, Canada), and at the National Cancer Institute (Bethesda, Maryland). Dr. Zauderer holds a Ph.D. in cell biology from the Massachusetts Institute of Technology. He is also a member of the board of directors of the New York Biotechnology Association (NYBA).

Ernest Smith, Ph.D. – Vice President of Research and CSO

Dr. Smith joined Vaccinex at its inception and was a key developer of its core cDNA library and antibody discovery technologies. Previously a research scientist at the University of Rochester, Dr. Smith is an experienced molecular and cellular immunologist with the skills and expertise to lead the company's research efforts. He is listed as an inventor on Vaccinex patent applications covering novel gene discovery methods, antigen delivery systems, and selection of fully human monoclonal antibodies. Dr. Smith earned his Ph.D. in Microbiology and Immunology from the University of Rochester School of Medicine and his undergraduate degree from St. John Fisher College.

Raymond E. Watkins – Vice President of Operations and Officer

Mr. Watkins joined Vaccinex in 2001 as its Vice President of Operations and is responsible for manufacturing, quality and pre-clinical development activities. He has over twenty years of industry management experience in FDA-regulated biopharmaceutical and biotechnology businesses, serving in several senior management roles in product and technology development, biologics manufacturing, regulatory and quality assurance. While at Praxis Biologics/Wyeth-Lederle Vaccines (A division of American Home Products), he played a critical role in successful FDA licensing and commercialization of Haemophilus Influenza Type B (HIB) vaccine, and later the HIB conjugate vaccine. Immediately prior to joining Vaccinex, he was Director of Operations and Quality Systems, Australasia, at Life Technologies (A division of Invitrogen Corporation) where he was responsible for all aspects of R&D, manufacturing, quality, FDA/TGA regulatory affairs, and general business management. Mr. Watkins studied biology at the University of Rochester, and completed course work at Conesus College and the Center for Professional Advancement. He is a certified Zenger-Miller Frontline Leadership instructor, and is a member of the Parenteral Drug Association and the Regulatory Affairs Professional Society (RAPS).

Deborah Helleson – Vice President of Business Development / Consultant

Ms. Helleson began advising Vaccinex in 2003 and currently oversees the company’s business development initiatives. Previously she was Vice President of Business Development at Immunex Corporation in Seattle, WA where she negotiated numerous business agreements with biotechnology and pharmaceutical companies. Prior to Immunex, Ms. Helleson had over 13 years of sales and marketing experience for various pharmaceutical services firms.

Deepak Sahasrabudhe, M.D. – Vice President of Clinical Affairs

Dr. Sahasrabudhe co-founded Vaccinex and currently serves as its Vice President of Clinical Affairs. He is Professor of Medicine and Oncology at the University of Rochester School of Medicine and Dentistry and Director of the Multidisciplinary Genito-Urinary Oncology Clinic. Dr. Sahasrabudhe is a graduate of T.N. Medical College of Bombay University. He completed his internship and residency training at Albany Medical College and Fellowship in Hematology-Oncology at the University of North Carolina, Chapel Hill.

Shaun Martin, Ph.D. – Director of Pre-Clinical Research

Dr. Martin joined Vaccinex in 2005 as its Director of Pre-Clinical Research and is part of the team responsible for directing the transition of discovery-stage antibodies into lead drug candidates suitable for pre-clinical development. Dr. Martin has broad expertise in designing bio-safety programs for large therapeutic molecules, including antibodies, and has significant experience in facilitating the complex processes involved in evaluating the pharmacology and toxicology of therapeutic drug candidates. Prior to joining Vaccinex, he was Senior Director, Business Development for MDS Pharma Services, one of the world’s largest Contract Research Organizations ("CRO"). Dr. Martin received a BS in Biological Sciences from the University of Lancaster, UK, and a Ph.D. in Physiology from the University of Liverpool, UK. He did post-doctorate research at the University of Liverpool where he investigated intracellular cell signaling mechanisms and the control of insulin secretion and thyroid function. He later joined the University of Rochester School of Medicine as a Post-doctoral Fellow in Pharmacology, conducting research in the areas of receptor pharmacology and intracellular signaling mechanisms.

Robert B. Parker, Ph.D. – Director, Regulatory Affairs and Quality Systems

Dr. Parker joined Vaccinex in 2006 as its Director of Regulatory Affairs and Quality Systems. He has over 35 years of experience in the pharmaceutical industry, sixteen of these years serving in senior management roles in drug Regulatory Affairs for major pharmaceutical companies such as Fisons and Celltech, and most recently as Senior Director, Regulatory Affairs for Genzyme Corporation, one of the world's leading biopharmaceutical companies. Dr. Parker also has extensive experience in both research and applied pharmacology, serving in various scientific, development, and senior management positions at Warner-Lambert/Parke-Davis, Pennwalt, Rorer Group and SmithKline Beecham.